Cardio-oncology
Slaskie Centrum Chorob Serca W Zabrzu is involved in clinical research focused on protecting cardiac function during breast cancer treatment, with attention to chemotherapy-related cardiotoxicity and left ventricular ejection fraction preservation.
- Heart failure
- Anthracycline-induced cardiomyopathy
- Cardiac monitoring
The research activity centres on preventing treatment-related myocardial injury in patients exposed to cancer therapies associated with cardiac risk.
Heart failure prevention
The sponsor’s clinical interest includes strategies aimed at reducing progression to heart failure in patients at risk of drug-induced cardiac dysfunction, particularly in the setting of oncological care.
- Cardioprotection
- Ventricular function
- Structural heart damage
Its research landscape reflects a focus on maintaining cardiac performance during exposure to therapies that may compromise the left ventricle.
Breast cancer treatment-related cardiac safety
Clinical activity extends to the cardiac consequences of systemic breast cancer therapy, with interest in preventing deterioration of heart function during treatment.
- Oncology-associated cardiac risk
- Ultrasound assessment
- Cardiac surveillance
This area links oncology and cardiology through the evaluation of heart protection in patients receiving potentially cardiotoxic cancer care.
